Bayer seeks expansion of EU label for Xarelto

Bayer AG (Xetra:BAYN) submitted an MAA to EMA for oral Xarelto rivaroxaban to treat pulmonary embolism (PE) and to prevent recurrent deep vein thrombosis (DVT) and PE. Bayer is seeking approval for the direct Factor Xa inhibitor based on data from the Phase III EINSTEIN-PE trial presented last month (see BioCentury Extra, March 26). ...